Litcius/Paper detail

Ligand-based discovery of coronavirus main protease inhibitors using MACAW molecular embeddings

Jie Dong, Mihayl Varbanov, Stéphanie Philippot, Fanny Vreken, Wenbin Zeng, Vincent Blay

2022Journal of Enzyme Inhibition and Medicinal Chemistry18 citationsDOIOpen Access PDF

Abstract

Ligand-based drug design methods are thought to require large experimental datasets to become useful for virtual screening. In this work, we propose a computational strategy to design novel inhibitors of coronavirus main protease, Mpro. The pipeline integrates publicly available screening and binding affinity data in a two-stage machine-learning model using the recent MACAW embeddings. Once trained, the model can be deployed to rapidly screen large libraries of molecules in silico. Several hundred thousand compounds were virtually screened and 10 of them were selected for experimental testing. From these 10 compounds, 8 showed a clear inhibitory effect on recombinant Mpro, with half-maximal inhibitory concentration values (IC50) in the range 0.18–18.82 μM. Cellular assays were also conducted to evaluate cytotoxic, haemolytic, and antiviral properties. A promising lead compound against coronavirus Mpro was identified with dose-dependent inhibition of virus infectivity and minimal toxicity on human MRC-5 cells.

Topics & Concepts

Virtual screeningIn silicoComputational biologyProteaseCoronavirusLigand (biochemistry)Drug discoveryChemistryDocking (animal)BiologyBiochemistryCoronavirus disease 2019 (COVID-19)EnzymeMedicineInfectious disease (medical specialty)ReceptorPathologyNursingDiseaseGeneComputational Drug Discovery MethodsSynthesis and biological activitySARS-CoV-2 and COVID-19 Research